Baseline characteristics of patients and medical therapy upon hospital admission.

<p>*Recurrent MI, stroke, major bleed, CHF/shock, arrhythmia, renal failure;</p><p>MI—myocardial infarction, ACEI—angiotensin-converting enzyme inhibitor, ARB—angiotensin II receptor blockers, PCI—percutaneous coronary intervention, CABG—coronary artery bypass grafting, TIA—transient ischaemic attack, AHF—acute heart failure.</p><p>Baseline characteristics of patients and medical therapy upon hospital admission.</p

Predictive accuracy of scoring models for rehospitalisation due to ADHF during a three-year follow-up period.

<p>Predictive accuracy of scoring models for rehospitalisation due to ADHF during a three-year follow-up period.</p

Predictive accuracy of scoring models for mortality during a three-year follow-up period.

<p>Predictive accuracy of scoring models for mortality during a three-year follow-up period.</p

Risk-scoring models and their components.

<p>*Recurrent MI, stroke, major bleed, CHF/shock, arrhythmia, renal failure.</p><p>BP—blood pressure, LBBB—left bundle branch block; PCI—percutaneous coronary intervention.</p><p>Risk-scoring models and their components.</p

Characteristics of laboratory tests and invasive procedures.

<p>IRA—infarct-related artery, LAD—left anterior descending artery, CABG—coronary artery bypass graft, RCA—right coronary artery, RPLD—ramus posterolateral dexter, RIVP—ramus interventricularis posterior, RCx—ramus circumflexus, RMS—ramus marginalis sinister, RIM—ramus intermedius, RD—ramus diagonalis, BNP—brain natriuretic peptide, LVEF—left ventricular ejection fraction.</p><p>Characteristics of laboratory tests and invasive procedures.</p

Landmark analyses of mortality after STEMI.

<p>Landmark analyses of mortality after STEMI.</p

Cumulative occurrence of mortality and repeat hospitalisation for ADHF over time.

<p>Cumulative occurrence of mortality and repeat hospitalisation for ADHF over time.</p

Baseline characteristics.

1<p>Categorical parameters are described by absolute number and percentage of patients in given category; continuous variables are described by median (5^th; 95^th percentile).</p>2<p>Overall statistical significance of differences among groups is based on Mann-Whitney test for continuous variables and ML chi-square test for categorical variables,</p>3<p>Creatinine clearance was estimated according to MDRD formula;</p>*<p>statistically significant.</p><p>BMI – Body mass index, TIA – Transitory ischemic attack, EF LV – Ejection fraction of left ventricle, PA systolic – Pulmonary artery systolic pressure, AVA – Aortic valve area.</p

Evaluation of additional benefit of biomarkers to clinical model (EuroSCORE) by net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) for prediction of combined safety endpoint at 30 days and combined endpoint (0–365 days) in groups of patients treated by TAVI and by SAVR and TAVI.

<p>Evaluation of additional benefit of biomarkers to clinical model (EuroSCORE) by net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) for prediction of combined safety endpoint at 30 days and combined endpoint (0–365 days) in groups of patients treated by TAVI and by SAVR and TAVI.</p

Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI group (N = 29).

<p>Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI group (N = 29).</p